HC Wainwright Has Pessimistic Outlook of JANX Q1 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Research analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Janux Therapeutics in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.48) for the quarter, down from their prior estimate of ($0.46). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $2.82 EPS.

JANX has been the subject of a number of other reports. Stifel Nicolaus increased their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. BTIG Research lifted their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, Wedbush restated an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Janux Therapeutics currently has an average rating of “Buy” and an average price target of $88.00.

Janux Therapeutics Trading Down 2.4 %

Janux Therapeutics stock opened at $30.75 on Thursday. Janux Therapeutics has a twelve month low of $29.63 and a twelve month high of $71.71. The stock has a 50 day moving average of $41.74 and a two-hundred day moving average of $47.55. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -26.28 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its position in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after acquiring an additional 442 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at $59,000. Plato Investment Management Ltd lifted its position in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after acquiring an additional 187 shares in the last quarter. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at $139,000. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at $159,000. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at $2,640,768.85. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,002 shares of company stock worth $2,684,703. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.